This specialized blood test can identify the presence of tumor cells in their earliest possible stage; is far less invasive than a traditional tissue biopsy; and can be used for both screening and surveillance.
At Mount Sinai’s Head and Neck Institute, early cancer detection is increasingly being conducted via liquid biopsy in concert with—and in certain cancers as a replacement for—tissue biopsy. Quickly becoming a critical standard of care component, the specialized blood test can identify the presence of tumor cells in their earliest possible stage; is far less invasive than a traditional tissue biopsy; and can be used for both screening and surveillance.
